Celgene Corp.’s Revlimid (lenalidomide) has added a new indication for relapsed/refractory mantle cell lymphoma but might soon face competition in this setting from Pharmacyclics Inc./Johnson & Johnson’s “breakthrough therapy” ibrutinib.
On June 5, FDA approved Celgene’s supplemental NDA for treatment of patients with mantle cell lymphoma (MCL) whose disease has...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?